Preclinical risk assessment of drug-induced hypo- and hyperprolactinemia

✍ Scribed by Adam Hargreaves; Johannes Harleman

• Book ID: 102290013
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 319 KB
• Volume: 31
• Category: Article
• ISSN: 0260-437X
• DOI: 10.1002/jat.1723

✦ Synopsis

ABSTRACT

Drug‐induced changes in prolactin signaling may obscure interpretation of preclinical toxicological endpoints. However, with informed consideration, classic hallmarks of hypo‐/hyperprolactinemia can be recognized in short‐ and long‐term rodent bioassays. Findings can be supported and expanded with additional in vivo and in vitro datasets. When taken together with human epidemiological evidence pertaining to the consequences of drug‐induced hypo‐/hyperprolactinemia, such findings permit both an analysis of human relevance and an assessment of human risk. Copyright © 2011 John Wiley & Sons, Ltd.